CVM (CEL-SCI Corporation) Company Total Assets

Official company branding of cel-sci.com (CVM)

CEL-SCI Corporation (CVM) is managed by a stable executive team ensuring transparency across all legal and medical processes. The market trend of the asset shown on this price chart reflects total assets at 20.84. The company is developing a closed-loop environment for head and neck cancer therapy, where customer retention is maximized, although expansion is constrained by stringent FDA requirements. Business revenues are based on the implementation of Multikine through partnerships with surgeons and insurers.

CVM - CEL-SCI Corp Company Total Assets over the range 07/04/2022 - 10/30/2026
Signature product of CEL-SCI Corp.

This indicator reflects the total volume of resources of CEL-SCI Corporation (CVM), combining equity and liabilities through a reverse calculation of return on assets (ROA). By analyzing the gross assets metric, investors assess capital management efficiency, which is critical for CEL-SCI Corporation (CVM) when financing costly developments of immunotherapy drugs to combat head and neck oncology.

Direct competitors

Cumulative Company Assets beigene.com|HALO (Halozyme) - Company Total Assets|Company Total Assets Revolution Medicines Inc|Aggregate Company Assets Ascentage (AAPG)|CG Oncology Therapeutics - Total Business Assets|Company Total Assets URGN (UroGen Pharma Ltd.)|BCAX - Cumulative Company Assets|Personalis - Company Total Assets|Company Assets Erasca Inc|Delcath (DCTH) - Aggregate Company Assets|Y-mAbs Corp - Aggregate Asset Value|Cumulative Company Assets AURA|CADL: Aggregate Asset Value|Company Total Assets ARAY|Cumulative Company Assets sellaslifesciences.com SLS|Actuate Therapeutics, Inc - Cumulative Company Assets|Company Total Assets Citius Oncology Inc CTOR|HURA - Aggregate Company Assets|Aggregate Asset Value TARA (protaratx.com)|FATE: Company Total Assets|Company Assets Aadi Bioscience (WHWK)|TCRX (TScan Therapeutics Inc) - Company Total Assets|Cumulative Company Assets Champions Oncology Corp (CSBR)|Company Total Assets XBIT|OSTX - Company Assets|Aggregate Company Assets Radiopharm Theranostics RADX|Artiva Biotherapeutics Inc. - Aggregate Company Assets|ANL: Cumulative Company Assets|Company Balance Sheet Assets Veru Corporation (VERU)|Tempest Therapeutics (TPST) - Aggregate Company Assets|XLO - Company Total Asset Base|RENB (Renovaro Biosciences) - Company Total Assets|Cumulative Company Assets Mural Bio (MURA)|Company Total Assets KAPA|Company Total Asset Base onkuretherapeutics.com|CytoMed Therapeutics Limited - Cumulative Company Assets|Aggregate Asset Value CRIS|Apollomics Corp - Company Total Assets|Tharimmune Inc (THAR) - Cumulative Company Assets|advanbiomed.com (ADVB) - Aggregate Company Assets|Company Assets Genprex Inc (GNPX)|Aggregate Company Assets Calidi Biotherapeutics Inc.|SBFM: Aggregate Asset Value|Aggregate Company Assets Xenetic Biosciences (XBIO)|SLRX: Total Asset Value of Company|Aggregate Company Assets Purple Biotech Corp PPBT|American Oncology Network Inc (AONC) - Company Assets|BGNE - Aggregate Company Assets|Aggregate Asset Value CKPT (checkpointtx.com)|ELEV: Company Total Assets|iCAD (ICAD) - Company Total Assets|Cumulative Company Assets IKNA|NTBL (Notable Labs Corp) - Aggregate Business Assets|Company Total Assets VIRX|Company Total Asset Base morphosys.com|Aggregate Company Assets NAYA Biosciences Inc. NAYA|Ascentage Pharma Group International (AAPGV) - Company Assets